Sign in
CompletedPhase 4

Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)

Key facts

Who runs it
Ohio State University
Where
Columbus, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 4
People taking part
56 people enrolled
Started
19 Oct 2023
Ended
1 May 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Patient-led Insulin (intervention group)
  • Provider-led Insulin (standard care)
Record updated
2 July 2025

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Pregnant individuals with a diagnosis of Gestational diabetes mellitus (GDM) between 20 0/7 to 31 6/7 - 32 6/7 weeks and requiring initiation of basal insulin initiation as determined by provider
  • Patients not on insulin or insulin initiation within 7 days of consent and randomization
  • ≥ 18 years old with the ability to give informed consent
  • Diagnosed with GDM during pregnancy by a one-hour 50-gram glucose challenge test ≥200 mg/dL at greater than 20 weeks of gestation or two elevated values on a 3-hour or a 100-gram glucose tolerance test at greater than 20 weeks of gestation
  • English or Spanish speaking
  • Receiving prenatal care at OSU or an affiliated clinic where Electronic Health Records (EHR) can be accessed

Who cannot take part

  • Type 1 or 2 diabetes
  • Insulin allergy
  • Not English or Spanish speaking

Where in United States

  • The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal MedicineColumbus, United States

About the trial

What the trial wants to find out

We propose a pragmatic, unblinded, randomized controlled, single center trial of 56 pregnant individuals with Gestational diabetes mellitus (GDM). Our study proposes a pragmatic randomized control trial of patient led rapid titration of basal insulin compared to standard therapy. There is a planned subgroup analysis of patients with and without concomitant metformin usage. Patients will continue routine clinic visits. Patients who are initiated on basal insulin or started on night-time basal insulin within 7 days will be approached about the study. Patients who agree to be enrolled will sign informed consent.

The 2 groups in the trial

  • Patient-led self-titration of insulinTreatment being tested

    Individuals randomized to this arm will initiate night-time insulin of 10 units. The type of basal insulin will be left to the discretion of the provider with levemir or glargine preferred over NPH. On day 0 of initiation of insulin, the patient will initiate night-time (or prior to sleep if alternate sleep schedule) insulin of 10 units (glargine, detemir, or NPH). Patient will check their fasting blood glucose in the morning and record their values. If the value is below 70 they will decrease their insulin dosage that night by 2 units; if the value is above 95 they will increase their insulin dosage that night by 2 units; and if the value is between 70 and 95, they will maintain the same insulin dosage that night. The patients will continue this algorithm for the remainder of the pregnancy. If the patient does not have a fasting blood glucose, the patient will maintain the dose of basal insulin at the prior dose.

    Treatment: Patient-led Insulin (intervention group)

  • Standard of careExisting treatment, for comparison

    Individuals randomized to this arm will receive standard care and titration of insulin will be determined by the individual providers.

    Treatment: Provider-led Insulin (standard care)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes
Publications
Record updated
2 July 2025